How the merger of MNC giants Bayer and Monsanto is likely to pan out in India

Biosimilars are a different ball game -- more complex and more expensive, essentially because biotech drugs, by their very nature, require understanding of living organisms

The USFDA's Office of Manufacturing Quality (OMQ) at the Centre for Drug Evaluation Research (CDER) evaluates compliance with cGMP for drugs based on inspection reports and evidence gathered by USFDA investigators

Share Market LIVE : On Thursday, Tata Motors, SBI, YES Bank, Tata Steel, Vedanta were among the top gainers. ONGC, Bharti Airtel, Bharti Infratel, HCl Tech and Infosys were among the top losers.    

Ujjivan Small Finance Bank, Vodafone Idea, YES Bank, Bharti Airtel, Maruti,CCD, Zydus Cadila, Adani Transmission Limited, Ultratech Cement are among the top stocks to watch out for Thursday's trading session

A number of biologics with huge markets are going off-patent in the US. Do Indian pharmaceutical companies have it in them to play this high-cost, high-risk game of launching biosimilars?

Cadila Healthcare share price has lost 29% in one year and fallen 27% since the beginning of this year

Following the acquisition of the remaining 15% stake each in its subsidiaries Zydus Technologies Ltd and Zydus Noveltech Inc, the two companies will become wholly-owned subsidiaries of Cadila Healthcare Ltd

The divestment will curtail 13 per cent global revenues of Lupin, which had posted Rs 16,369 crore consolidated revenues for the financial year ended March 31, 2019

Most violations relate to rectifiable documentation, data maintenance, batch-wise consistent production quality, data on supply chain, stability issues, microbial contamination and quality checks

The USFDA warning letter will not affect the existing business of Cadila Healthcare in the US and the existing product supplies from the Moraiya facility will continue

Cadila Healthcare share which opened at Rs 257 against previous close of Rs 255.30 hit an intra day high of Rs 260.6 (2.08%)

Ranitidine, an old molecule with sales of $412.4 million is found to have cancer-causing impurities

Even as smaller Indian companies are looking to grow their business in the US market, the larger focus is on leading pharma companies because the top 20 of them contribute 75 per cent to total pharma exports from India

Drug firm Cadila Healthcare on Friday reported a consolidated net profit of Rs 303.6 crore for the quarter ended June 30, 2019.

Analysts expect a better show in Q1 thanks to a combination of factors such as overall business improvement in the Unites States and a pick-up in demand in the domestic market.

Zydus Cadila, India's fourth-largest drug company by revenue, is banking big on research of new drugs, even though others have bowed out. Zydus expects the new drug business to grow to Rs 3,500 crore in four-five years

In spite of an expanding healthcare market, prevention and wellness do not get the attention they deserve

Focus should be on preventive product development to help promote people's wellness over a long period